| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
Katherine Bach Kalin is Director at SLS. Katherine Bach Kalin's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $1.4M at current prices.
Net of sales, the SLS filings show accumulation of 83,400 shares.
Katherine Bach Kalin has 7 Form 4 filings on record from August 2022 to January 2026, all as Director at SELLAS Life Sciences Group (SLS), 2022–2026.
The 10 reported transactions were 4 stock awards, 4 option or other derivative awards and 2 open-market purchases.
Counted by filing, the open-market trades come to 2 purchases worth about $137K and no sales.
The largest open-market purchase was 63,400 shares of SLS at an average $1.59 on November 19, 2025, about $101K.